These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2597340)

  • 21. Haloperidol conditioned catalepsy in rats: a possible role for D1-like receptors.
    Banasikowski TJ; Beninger RJ
    Int J Neuropsychopharmacol; 2012 Nov; 15(10):1525-34. PubMed ID: 22093169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similarities between the akinesia induced by carbachol microinjections into the pontine reticular formation and neuroleptic catalepsy.
    Elazar Z; Paz M
    Life Sci; 1992; 51(17):1373-80. PubMed ID: 1406055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosomatostatin- and haloperidol-induced catalepsy in Wistar rats: Differential responsiveness to sleep deprivation.
    Ionov ID; Pushinskaya II; Gorev NP; Frenkel DD
    Neurosci Lett; 2018 Sep; 684():72-77. PubMed ID: 29990558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response.
    Hillegaart V; Ahlenius S; Magnusson O; Fowler CJ
    Pharmacol Biochem Behav; 1987 May; 27(1):159-64. PubMed ID: 3615537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats.
    Millan MJ; Gressier H; Brocco M
    Eur J Pharmacol; 1997 Mar; 321(3):R7-9. PubMed ID: 9085054
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Partial 6-hydroxydopamine-induced lesions and haloperidol-induced catalepsy.
    Johnson SK; Fisher H; Wagner GC
    Neuropharmacology; 1993 Mar; 32(3):273-8. PubMed ID: 8474623
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of piracetam, a cyclic GABA analogue, on haloperidol-induced catalepsy in the rat.
    Balsara JJ; Bapat TR; Chandorkar AG
    Indian J Physiol Pharmacol; 1980; 24(3):227-32. PubMed ID: 7193183
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration.
    Lappalainen J; Hietala J; Syvälahti E
    Psychopharmacology (Berl); 1989; 98(4):472-5. PubMed ID: 2570432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. K-channel blockers attenuate the presynaptic effects of the D2/D3 agonist quinpirole in monkeys.
    Rosenzweig-Lipson S; Barrett JE
    Pharmacol Biochem Behav; 1995 Aug; 51(4):843-8. PubMed ID: 7675867
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Hyperprolactinemia and catalepsy induced by haloperidol].
    Reggio A; Condorelli DF; De Simone D; Giammona G; Maccagnano C; Panico AM; Tigano G
    Boll Soc Ital Biol Sper; 1981 Aug; 57(16):1655-9. PubMed ID: 7197982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-lasting resistance to haloperidol-induced catalepsy in male rats chronically treated with caffeine.
    Góngora-Alfaro JL; Moo-Puc RE; Villanueva-Toledo JR; Alvarez-Cervera FJ; Bata-García JL; Heredia-López FJ; Pineda JC
    Neurosci Lett; 2009 Oct; 463(3):210-4. PubMed ID: 19654037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adenosine A2 receptors modulate haloperidol-induced catalepsy in rats.
    Mandhane SN; Chopde CT; Ghosh AK
    Eur J Pharmacol; 1997 Jun; 328(2-3):135-41. PubMed ID: 9218695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy.
    Prinssen EP; Colpaert FC; Koek W
    Eur J Pharmacol; 2002 Oct; 453(2-3):217-21. PubMed ID: 12398907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerance of haloperidol catalepsy.
    Ezrin-Waters C; Seeman P
    Eur J Pharmacol; 1977 Feb; 41(3):321-7. PubMed ID: 556989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A possible participation of gonadotropin-releasing hormone in the neuroleptic and cataleptic effect of haloperidol.
    Umathe SN; Wanjari MM; Manna SS; Jain NS
    Neuropeptides; 2009 Jun; 43(3):251-7. PubMed ID: 19403167
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alteration of cataleptic responses induced by dopamine receptor antagonists after chronic cocaine administration in mice.
    Ushijima I; Mizuki Y; Yamada M
    Eur J Pharmacol; 1995 Oct; 285(1):55-9. PubMed ID: 8846811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy.
    Sevak RJ; Koek W; France CP
    Eur J Pharmacol; 2005 Jul; 517(1-2):64-7. PubMed ID: 15975572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of age and isolation on the evolution of catalepsy during chronic haloperidol treatment.
    Frussa-Filho R; Otoboni JR; Uema FT; Palermo-Neto J
    Braz J Med Biol Res; 1992; 25(9):925-8. PubMed ID: 1342840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Righting elicited by novel or familiar auditory or vestibular stimulation in the haloperidol-treated rat: rat posturography as a model to study anticipatory motor control.
    Clark CA; Sacrey LA; Whishaw IQ
    J Neurosci Methods; 2009 Sep; 182(2):266-71. PubMed ID: 19559052
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Caffeine and muscarinic antagonists act in synergy to inhibit haloperidol-induced catalepsy.
    Moo-Puc RE; Góngora-Alfaro JL; Alvarez-Cervera FJ; Pineda JC; Arankowsky-Sandoval G; Heredia-López F
    Neuropharmacology; 2003 Sep; 45(4):493-503. PubMed ID: 12907310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.